目的:研究银翘散联合头孢哌酮/舒巴坦联合治疗社区获得性肺炎(community-acquirted pneumonia,CAP)的疗效与安全性。方法:选择120例社区获得性肺炎作为研究对象,随机分为两组,每组60例。对照组给予注射用头孢哌酮钠/舒巴坦钠治疗,观察组在对照组治疗的基础上采用银翘散治疗。观察两组患者临床疗效、肺部感染评分、药物浓度达到峰值的时间(Tmax)、达到峰值的浓度(Cmax)以及药物的半衰期(t1/2)及不良反应情况。结果:观察组治疗有效率高达98.3%,显著高于对照组治疗有效率80.0%,差异具有显著统计学意义(P<0.05)。观察组临床肺部感染评分(CPIS)于治疗后5 d起明显低于治疗前、早于对照组;药物浓度峰值Cmax与对照组无差异。观察组达到峰值的时间Tmax、半衰期t1/2时间显著短于对照组,差异具有显著统计学意义(P<0.05)。观察组总体生活质量高达(81.84±8.34)分,显著高于对照组(69.42±6.14)分,差异具有显著统计学意义(P<0.05)。观察组发生头晕头痛、恶心呕吐、腹部不适、皮疹、肝功能损害及肾功能损害等不良反应例数均显著少于对照组,差异均具有显著统计学意义(P<0.05)。结论:银翘散联合头孢哌酮/舒巴坦治疗代谢快、疗效好、不良反应少,具有积极的临床价值。 Objective: To study the efficacy and safety of combining Yinqiao Powder and cefoperazone / sulbactam in the treatment of community-acquired pneumonia (CAP). Methods: 120 cases of community-acquired pneumonia were selected as research objects and randomly divided into two groups of 60 cases. The control group was given cefoperazone sodium / sulbactam sodium for injection. The observation group was treated with Yinqiao Powder on the basis of the control group. The clinical efficacy, lung infection score, time to peak (Tmax), peak (Cmax), half-life (t1 / 2) and adverse reactions of the two groups were observed. Results: The effective rate of the observation group was 98.3%, which was significantly higher than that of the control group (80.0%), the difference was statistically significant (P <0.05). The clinical lung infection score (CPIS) in observation group was significantly lower than that before treatment and 5 d after treatment, and the peak value of drug concentration Cmax was not significantly different from that in control group. The peak time of observation group Tmax, half-life t1 / 2 time was significantly shorter than the control group, the difference was statistically significant (P <0.05). The overall quality of life of the observation group was as high as (81.84 ± 8.34) points, which was significantly higher than that of the control group (69.42 ± 6.14), the difference was statistically significant (P <0.05). The number of adverse reactions in the observation group such as dizziness, headache, nausea, vomiting, abdominal discomfort, skin rash, liver dysfunction and renal dysfunction were significantly less than those in the control group, with significant differences (P <0.05). Conclusion: Yinqiao combined cefoperazone / sulbactam treatment has the advantages of fast metabolism, good curative effect and few adverse reactions, which has a positive clinical value.